scispace - formally typeset
Journal ArticleDOI

Long-term follow-up of patients with hyperprolactinaemia.

TLDR
To determine the frequency with which hyperprolactinaemic illnes tends to resolve with time, a method called AIM’s “AIM ” is used.
Abstract
AIM To determine the frequency with which hyperprolactinaemic illnes tends to resolve with time. STUDY DESIGN A retrospective case-notes review from a specialist endocrine unit in a provincial teaching hospital and tertiary referral centre. PATIENTS Seventy women with hyperprolactinaemia referred to the unit in the 15 year period between May 1979 and May 1994. All those with a non-pituitary cause or with macroadenoma had been excluded, as were those who did not have high-resolution imaging, or who were on treatment at the time of referral. INTERVENTION Intermittent course of treatment with dopamine receptor agonists according to individual need. ENDPOINTS Latest serum PRL concentration in those who had discontinued treatment, and whether serum PRL tended to be lower in any particular group RESULTS There was a significant fall in median PRL concentration from 2000 (714–8000) to 1000 mU/l (220–5600) in the 31 women who had discontinued therapy (P<0.0005), and serum PRL was normal (<700 mU/l) in 11 of them. Serum PRL also fell to normal in three of ten women who had no treatment at all. Final PRL concentration was normal in 35% of women who had had at least one pregnancy during the period of follow-up compared to 14% who had not (P<0.05). CONCLUSIONS These data confirm the findings of others that hyperprolactinaemia will prove self-limiting in up to one-third of women, and that pregnancy may be one factor which triggers a return to normal function

read more

Citations
More filters
Journal ArticleDOI

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline

TL;DR: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence for diagnosis and treatment of hyperprolactinemia.
Journal ArticleDOI

Advances in the treatment of prolactinomas.

TL;DR: A critical analysis of the efficacy and safety of the various modes of therapy available for the treatment of patients with prolactinomas with an emphasis on challenging situations is provided, a discussion of the data regarding withdrawal of medical therapy, and a foreshadowing of novel approaches to therapy that may become available in the future.
Journal ArticleDOI

Mechanisms for pituitary tumorigenesis: the plastic pituitary.

TL;DR: The mechanisms underlying hereditary pituitsary hypoplasia, reversible pituitary hyperplasia, excess hormone production, and tumor initiation and promotion associated with normal and abnormal pituitaries differentiation in health and disease are discussed.
Journal ArticleDOI

Angiogenesis in endocrine tumors.

TL;DR: An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.
References
More filters
Journal ArticleDOI

Long-term effect of a first pregnancy on the secretion of prolactin

TL;DR: A first pregnancy leads to a long-term decrease in serum prolactin secretion, lasting at least 12 to 13 years, which is known to protect against subsequent breast cancer.
Journal ArticleDOI

Microadenomas of the Pituitary and Abnormal Sellar Tomograms in an Unselected Autopsy Series

TL;DR: PROLACTIN-SECRETING microadenomas of the pituitary gland have been diagnosed on the basis of elevated serum prolactin concentrations and abnormal tomograms of the sella turcica.
Journal ArticleDOI

The Natural History of Idiopathic Hyperprolactinemia

TL;DR: The data clearly challenge the use of ablative pituitary therapy for IH and raises questions of the benefit of chronic medical therapy for this condition.
Journal ArticleDOI

Natural history of microprolactinomas: six-year follow-up.

TL;DR: A 6-year follow-up of patients harboring microprolactinomas suggests that few patients demonstrate significant growth of their tumor during this time, and this short term risk of tumor growth (about 10%) must be weighed in the decision about therapeutic endeavors.
Related Papers (5)